Dr. Nancy Nixon

Nancy Nixon



Clinical Assistant Professor

Cumming School of Medicine, Department of Oncology


Arnie Charbonneau Cancer Institute

Contact information

Phone number

Office: 403.521.3912

For media enquiries, contact

Kelly Johnston
Senior Communications Specialist

Please submit your media request here


Preferred method of communication

Admin Assistant

Charmaine McLean

Email: charmaine.mclean@ahs.ca

Office: 403.521.3912



Dr. Nancy Nixon received a degree in biochemistry with honours from the University of Calgary in 2008 prior to medical school which she completed in 2011. She did her internal medicine and medical oncology specialization training in Calgary, finishing in 2016. In 2017, Dr. Nixon completed a clinical and research fellowship in breast cancer under the supervision of Dr. Sunil Verma. She is currently a full time medical oncologist at the Tom Baker Cancer Centre and Assistant Professor at the University of Calgary. In 2017 she received an Early Career Research Program Award from the Canadian Institute of Health Research, and was featured in the Alberta Cancer Foundation’s LEAP magazine for her research focusing on patient priorities in cancer research. Dr. Nixon is also involved with translational research studies at the University of Calgary examining biomarkers for tumour response to treatment and immune therapies. She has received over $1,500,000.00 CAD funding for her research endeavors over since taking on her current position at the Tom Baker.  Apart from her clinical and research duties Dr. Nixon is also team captain for the Tom Baker Cancer Conquerors in the Alberta Ride to Conquer Cancer, who have raised close to $1 million in research funds for the Tom Baker since 2016.



Areas of Research

Area of Focus
  • Breast Cancer
Summary of Research

Dr. Nixon is involved in clinical, translational, and health services research. Within the health services realm, since completing the James Lind Alliance study for metastatic breast cancer in 2017, she has started patient priority projects for young women with breast cancer, and for patients with early stage colon cancer in Canada. In 2019, she received funding as primary investigator for an investigator initiated trial (IIT) looking at the utility of electronic patient reported outcomes for symptom monitoring. Within the clinical and translational realms, in 2019 she secured funding as co-investigator for a phase 2 clinical IIT evaluating a novel immune therapy combination in triple negative breast cancer. She will serve as primary investigator on the translational correlative aspects for this study with local funding. Since 2018 she has been co-investigator on a study looking at early blood markers of bone recurrence in breast cancer patient, a project that has been granted both an early cancer detection initiative grant, and Canadian Institute of Health Research (CIHR) grant.  She is currently the primary investigator on two studies that are ongoing, one prospective study looking at the effect of the cdk4/6 inhibitor palbociclib on bone turnover, and a second retrospective study evaluating the tumour immunobiome of patients with HER2-positive breast cancer.